As midostaurin has not been investigated largely in wt FLT3‐expressing AML pre‐clinically, we sought to explore its activity in this context, alone and in combination, to better understand the observed clinical efficacy and inform best combinations for future clinical investigation. The gene discussed is FLT3; the disease is acute myeloid leukemia.